Market Cap 12.23M
Revenue (ttm) 0.00
Net Income (ttm) -9.00M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 7,500
Avg Vol 44,730
Day's Range N/A - N/A
Shares Out 7.19M
Stochastic %K 17%
Beta 0.51
Analysts Strong Sell
Price Target $15.00

Company Profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemi...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 77 331 0156
Address:
Building C, 10th Floor 10 Habarzel Street, Tel Aviv-Yafo, Israel
Stockhunter008
Stockhunter008 May. 16 at 1:39 AM
On September 26, 2025, the trading volume for $SPRB was 800 shares. Today, the trading volume for $CMMB was 7500 shares.
0 · Reply
Zdxss1
Zdxss1 May. 15 at 7:58 PM
$CMMB The administration said In the first quarter we continued to have productive discussions with potential strategic partners while releasing new data analyses.. We are close to announcing a partnership of some kind or an acquisition.
1 · Reply
cayman777
cayman777 May. 15 at 2:38 PM
$CMMB -👀
2 · Reply
Stockhunter008
Stockhunter008 May. 15 at 1:41 AM
$CMMB "Company Continues to Advance Multiple Partnering Options for Nebokitug"
0 · Reply
Newmoves
Newmoves May. 15 at 12:53 AM
$CMMB beyond disappointing all these great results and partnership talks, and the stock continues to go nowhere. It’s been all talk for many years now. 
0 · Reply
Zdxss1
Zdxss1 May. 14 at 8:17 PM
$CMMB The company announced that Q1 (January – March) discussions were “fruitful.” • This wording suggests tangible progress, not just ongoing negotiations. • Then, in late Q1 on March 19, management requested shareholder approval to raise the maximum share size and obtain authorization. • The timing indicates a clear link: it is likely that the “fruitful discussions” created scenarios where the company needed flexibility — either to structure the deal, to meet partner conditions, or to prepare for multiple options. In other words, the March 19 request appears to be the result of the development of discussions and reaching an agreement. We hope this is the scenario.
0 · Reply
Kazinovsky
Kazinovsky May. 14 at 7:56 PM
$CMMB Down 4.32%. 0.42$ pre-split! Guess I'm not the only one fed up with this never ending saga!
0 · Reply
DLTT4489
DLTT4489 May. 14 at 7:15 PM
$CMMB did it hurt?🤪🤪🤑🤑
0 · Reply
DLTT4489
DLTT4489 May. 14 at 7:15 PM
$CMMB @shreyvakil @Snptrader and other pumpers 👇👇👇👇👇👇👇
0 · Reply
DLTT4489
DLTT4489 May. 14 at 6:41 PM
$CMMB is @shreyvakil still alive? 😁😁
0 · Reply
Latest News on CMMB
Chemomab Therapeutics sees cash runway through 1Q27

2026-03-19T12:11:46.000Z - 2 months ago

Chemomab Therapeutics sees cash runway through 1Q27


Chemomab Therapeutics reports FY25 EPS (1c) vs. (4c) last year

2026-03-19T12:05:34.000Z - 2 months ago

Chemomab Therapeutics reports FY25 EPS (1c) vs. (4c) last year


Chemomab Therapeutics reports Q3 EPS (0.4c) vs (1c) last year

2025-11-20T13:05:27.000Z - 6 months ago

Chemomab Therapeutics reports Q3 EPS (0.4c) vs (1c) last year


Chemomab Therapeutics management to meet with Maxim

2025-09-12T16:55:11.000Z - 8 months ago

Chemomab Therapeutics management to meet with Maxim


Chemomab Therapeutics Ltd – ADR trading halted, news pending

2025-08-25T23:50:06.000Z - 9 months ago

Chemomab Therapeutics Ltd – ADR trading halted, news pending


Chemomab Therapeutics reports Q2 EPS 0.4c vs 0.013c last year

2025-08-14T12:11:23.000Z - 9 months ago

Chemomab Therapeutics reports Q2 EPS 0.4c vs 0.013c last year


Chemomab Therapeutics management to meet with Maxim

2025-07-31T17:55:26.000Z - 10 months ago

Chemomab Therapeutics management to meet with Maxim


Chemomab Announces New Medical and Clinical Appointments

Apr 15, 2025, 8:00 AM EDT - 1 year ago

Chemomab Announces New Medical and Clinical Appointments


Chemomab Therapeutics Transcript: Study Result

Jul 25, 2024, 8:00 AM EDT - 1 year ago

Chemomab Therapeutics Transcript: Study Result


Chemomab Therapeutics Announces $10 Million Private Placement

Jul 25, 2024, 7:38 AM EDT - 1 year ago

Chemomab Therapeutics Announces $10 Million Private Placement


Chemomab Therapeutics Transcript: KOL Event

Apr 10, 2024, 10:00 AM EDT - 2 years ago

Chemomab Therapeutics Transcript: KOL Event


Stockhunter008
Stockhunter008 May. 16 at 1:39 AM
On September 26, 2025, the trading volume for $SPRB was 800 shares. Today, the trading volume for $CMMB was 7500 shares.
0 · Reply
Zdxss1
Zdxss1 May. 15 at 7:58 PM
$CMMB The administration said In the first quarter we continued to have productive discussions with potential strategic partners while releasing new data analyses.. We are close to announcing a partnership of some kind or an acquisition.
1 · Reply
cayman777
cayman777 May. 15 at 2:38 PM
$CMMB -👀
2 · Reply
Stockhunter008
Stockhunter008 May. 15 at 1:41 AM
$CMMB "Company Continues to Advance Multiple Partnering Options for Nebokitug"
0 · Reply
Newmoves
Newmoves May. 15 at 12:53 AM
$CMMB beyond disappointing all these great results and partnership talks, and the stock continues to go nowhere. It’s been all talk for many years now. 
0 · Reply
Zdxss1
Zdxss1 May. 14 at 8:17 PM
$CMMB The company announced that Q1 (January – March) discussions were “fruitful.” • This wording suggests tangible progress, not just ongoing negotiations. • Then, in late Q1 on March 19, management requested shareholder approval to raise the maximum share size and obtain authorization. • The timing indicates a clear link: it is likely that the “fruitful discussions” created scenarios where the company needed flexibility — either to structure the deal, to meet partner conditions, or to prepare for multiple options. In other words, the March 19 request appears to be the result of the development of discussions and reaching an agreement. We hope this is the scenario.
0 · Reply
Kazinovsky
Kazinovsky May. 14 at 7:56 PM
$CMMB Down 4.32%. 0.42$ pre-split! Guess I'm not the only one fed up with this never ending saga!
0 · Reply
DLTT4489
DLTT4489 May. 14 at 7:15 PM
$CMMB did it hurt?🤪🤪🤑🤑
0 · Reply
DLTT4489
DLTT4489 May. 14 at 7:15 PM
$CMMB @shreyvakil @Snptrader and other pumpers 👇👇👇👇👇👇👇
0 · Reply
DLTT4489
DLTT4489 May. 14 at 6:41 PM
$CMMB is @shreyvakil still alive? 😁😁
0 · Reply
Zdxss1
Zdxss1 May. 14 at 4:35 PM
$CMMB Despite the long wait and marathon talks, I believe the discussions are not about the drug itself as a medical or commercial asset. Instead, they are centered on the value of the deal — the amount demanded by the company versus the amount offered by interested parties. In this sense, the term “fruitful discussions” signals progress toward reaching a financial figure that satisfies both sides. “A very important point in this news is that reducing or injecting new shares is not part of the company’s goals or strategy. Instead, management is clearly focused on creating value through partnerships and external funding, which reassures investors that dilution is not on the table
0 · Reply
cayman777
cayman777 May. 14 at 3:37 PM
$CMMB -You either believe they are going to land a licensing agreement, partnership or fda btd or you don’t. The alternative will be dilution. Is the data that strong-time will tell.
0 · Reply
Kazinovsky
Kazinovsky May. 14 at 2:47 PM
$CMMB should read: And to make things worse, they now have access to $100M ... they can drag this out forever.
0 · Reply
Kazinovsky
Kazinovsky May. 14 at 2:45 PM
$CMMB Same old garbage. They have been talking about "ongoing strategic partnership" for over a year. Why is no one interested in this wonder drug? Also, where is the "Finalize Phase 3 Design" that was supposed to have happened in H2 2025? They have diluted the SP by 75% in one year. There were aprox 4M shares in Q1 2025, now we are at 7.2M! And to make things worse, they now have access to ... they can drag this out forever. Disappointed and tired of the same old crap.
1 · Reply
Tigerfromasia
Tigerfromasia May. 14 at 1:38 PM
$CMMB lets be honest. They might be doing terrific job scientifically but business-wise, they did nothing in 1Q. Quite disappointing.
0 · Reply
JoeShmoDoe
JoeShmoDoe May. 14 at 1:26 PM
$CMMB literally, no one ever buys this shit stock
0 · Reply
dom3
dom3 May. 14 at 1:18 PM
$CMMB I agree in the specific wording that productive is far more encouraging than active. Productive means progressing or having at least agreed to continue talking.
1 · Reply
W2Cap
W2Cap May. 14 at 12:38 PM
$CMMB it all sounds positive. But also doesn't sound like they've just inked a partnership deal or are about to sign one.
2 · Reply
cpatel2000
cpatel2000 May. 14 at 12:37 PM
$CMMB “In the first quarter we continued to have productive discussions with potential strategic partners while releasing new data analyses…” “Productive” is new language. Previous quarters used “active discussions,” “advancing discussions,” “continuing discussions.” Productive implies progress is being made, not just conversations occurring. The return of “Multiple Partnering Options” after Q4 2025’s narrowing is the single most important language development in this press release. It suggests the field has either re-expanded — potentially because the IBD angle attracted new parties
0 · Reply
Snptrader
Snptrader May. 14 at 12:26 PM
$CMMB https://investors.chemomab.com/2026-05-14-Chemomab-Therapeutics-Announces-First-Quarter-2026-Financial-Results-and-Provides-Corporate-Update
0 · Reply
W2Cap
W2Cap May. 14 at 12:24 PM
$CMMB Guessing it's AH rather than pre-market? the report
0 · Reply
DLTT4489
DLTT4489 May. 14 at 11:05 AM
$CMMB have you ever ask why this garbage has 5-10 shares trading befor matkets open? 😜😜
0 · Reply